Does MassHealth Cover Ozempic, Wegovy & Zepbound in 2026? (Updated)

Last updated: May 21, 2026 | Reading time: ~8 minutes | Reviewed by Dr. Marcus Tan, MD

Direct answer — MassHealth and GLP-1s in 2026

Yes — MassHealth (Massachusetts Medicaid) covers some GLP-1 drugs for type 2 diabetes, including Ozempic, Mounjaro, and Trulicity, typically with prior authorization. Coverage for the weight-loss-only indications (Wegovy, Zepbound, Saxenda) is more restricted: it generally requires prior authorization, a documented BMI threshold (commonly BMI of 30 or higher, or 27 with a weight-related comorbidity), and prior or concurrent lifestyle intervention. As of 2026, MassHealth has continued to expand obesity treatment coverage relative to many other state Medicaid programs, but specific criteria still vary by member plan.

Important — verify your specific plan

Insurance formularies change frequently. This guide reflects publicly available coverage details as of May 2026 — confirm coverage for your specific plan by calling MassHealth Customer Service at the number on the back of your MassHealth card, or by checking your plan’s drug formulary (the MassHealth Drug List, or MHDL) directly. If you are enrolled in a MassHealth managed care plan (such as a MassHealth ACO or MCO), call that plan’s member services line — formulary details may differ at the plan level.

MassHealth GLP-1 coverage at a glance

Drug	FDA-Approved Indication	MassHealth Coverage 2026	Prior Authorization?
Ozempic (semaglutide)	Type 2 diabetes	Covered	Often required
Wegovy (semaglutide)	Chronic weight management	Restricted — BMI and PA criteria	Yes
Mounjaro (tirzepatide)	Type 2 diabetes	Covered	Often required
Zepbound (tirzepatide)	Chronic weight management / OSA	Restricted — BMI and PA criteria	Yes
Saxenda (liraglutide)	Chronic weight management	Restricted	Yes
Trulicity (dulaglutide)	Type 2 diabetes	Covered	Often required

The pattern is consistent across most MassHealth plans: GLP-1s prescribed for type 2 diabetes are generally on-formulary with manageable prior authorization, while GLP-1s prescribed for the weight-loss indication face tighter criteria. For a broader state-by-state view, see our Medicaid GLP-1 by State 2026 guide.

Ozempic on MassHealth (2026)

Ozempic (semaglutide, injectable) is FDA-approved for type 2 diabetes. As of 2026, MassHealth generally covers Ozempic for members with a documented type 2 diabetes diagnosis, often after a trial of metformin or another first-line agent. Prior authorization is commonly required to confirm the diagnosis and step-therapy history.

What you typically need on file:
– A confirmed type 2 diabetes diagnosis (ICD-10 code).
– A recent A1C value documented in the chart.
– Documentation that metformin was tried, was not tolerated, or is contraindicated (criteria vary).

MassHealth does not cover Ozempic for weight loss as a primary indication, even though Ozempic and Wegovy are the same molecule (semaglutide). Prescribing Ozempic off-label for weight loss in a non-diabetic patient is unlikely to clear PA.

Wegovy on MassHealth (2026)

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management. MassHealth coverage in 2026 is restricted and gated by prior authorization. Based on publicly available MassHealth Drug List criteria as of May 2026, typical PA requirements include:

– A BMI of 30 or higher, or a BMI of 27 or higher with a documented weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease).
– Documentation of a structured weight-management attempt — commonly defined as at least three to six months of reduced-calorie diet and increased physical activity.
– Prescribing by a provider familiar with obesity pharmacotherapy.
– Periodic reauthorization (often every 3–6 months) showing meaningful weight loss to continue coverage.

If your weight loss does not meet the program’s response threshold at reauthorization (commonly around 5% body weight reduction at 12 weeks of therapy), continued coverage may be denied. Specific thresholds vary — confirm with your plan.

Zepbound on MassHealth (2026)

Zepbound (tirzepatide) is FDA-approved for chronic weight management and, as of late 2024, also for obstructive sleep apnea (OSA) in adults with obesity. MassHealth coverage in 2026 mirrors Wegovy: restricted, with PA, BMI, and ongoing-response criteria.

Notable points:
– The OSA indication may open a separate PA pathway for some members with documented moderate-to-severe sleep apnea on a sleep study.
– Step-therapy may apply — some plans require a trial of Wegovy first before approving Zepbound, or vice versa.
– Tirzepatide is dual-agonist (GIP + GLP-1), often produces greater weight loss than semaglutide in head-to-head data, but cost considerations in PA decisions can favor whichever the plan negotiated more favorably.

Mounjaro on MassHealth (2026)

Mounjaro (tirzepatide) is the type-2-diabetes-indicated version of the same molecule as Zepbound. Coverage is broader than Zepbound because it is being prescribed for diabetes rather than weight loss. Expect PA requirements similar to Ozempic: confirmed type 2 diabetes diagnosis, A1C documentation, and step-therapy with metformin.

As with Ozempic, prescribing Mounjaro off-label for weight loss in a non-diabetic member is unlikely to clear MassHealth PA.

What if MassHealth denies your GLP-1 prescription?

A denial is not the end of the road. Options in order of typical practicality:

1. Appeal the denial. You have a right to appeal any MassHealth coverage denial. The denial letter will include instructions and a deadline (typically 30 days). Your prescriber can submit a peer-to-peer review, additional clinical documentation (BMI trend, comorbidities, prior weight-loss attempts), and a letter of medical necessity.

2. Switch to a covered alternative. If you have type 2 diabetes, Ozempic, Mounjaro, or Trulicity may be options. If you are non-diabetic, ask your prescriber whether Saxenda (older liraglutide) has different PA hurdles in your plan.

3. Cash-pay via telehealth. Many MassHealth members who can’t get Wegovy or Zepbound approved end up using compounded semaglutide or tirzepatide through cash-pay telehealth services. These are not covered by MassHealth, but they’re often less expensive than brand-name retail.

See Remedy Meds GLP-1 pricing

4. Manufacturer patient-assistance programs. Novo Nordisk (Wegovy, Ozempic, Saxenda) and Eli Lilly (Zepbound, Mounjaro) operate patient-assistance programs for low-income patients. Eligibility and benefit amounts change — check the manufacturer sites directly.

GLP-1 alternatives for MassHealth members in 2026

If MassHealth won't cover your weight-loss GLP-1, the most common pivot is to a cash-pay telehealth program offering compounded semaglutide or tirzepatide. Important framing:

- Compounded GLP-1s are not covered by MassHealth. You pay out of pocket.
- Compounded does not mean FDA-approved. The active molecule has decades of safety data, but the specific compounded product has not gone through FDA approval.
- Pricing is typically far below retail. Cash-pay compounded GLP-1 programs in 2026 commonly run in the $200–$400 per month range, versus retail Wegovy or Zepbound list prices well above $1,000.
- FDA shortage list status drives compounding legality — as of 2026 this landscape has shifted from the 2023–2024 shortage era. Confirm with your provider that the formulation they are dispensing is legally compounded.

Our top picks for cash-pay GLP-1 telehealth as of May 2026:

Ro Body Program

Telehealth weight-loss program with branded GLP-1 access (when in stock) and a coaching layer. Strong clinical workflow; one of the most established players. Read our full Ro review.

Remedy Meds

Compounded-GLP-1 focused telehealth with transparent pricing. Frequently lower entry price than Ro's branded program. Read our Remedy Meds review.

See Remedy Meds pricing

For a side-by-side, see our GLP-1 provider comparison.

How to apply for prior authorization

Step-by-step, the MassHealth PA workflow for GLP-1 looks like this in 2026:

1. Doctor visit and chart documentation. Your prescriber documents your BMI, comorbidities, prior weight-management attempts, and clinical rationale.
2. PA form submission. Your prescriber's office submits the MassHealth PA request (typically via the MassHealth Drug List PA portal or fax). The form requires diagnosis, drug, dose, and supporting clinical detail.
3. MassHealth review. Standard turnaround is up to 14 days for non-urgent requests. Urgent requests can be expedited to 24–72 hours when clinically justified.
4. Decision letter. Approval, denial, or request for additional information arrives by mail and is available in the member portal.
5. If approved: PA is typically time-limited (3–12 months). Reauthorization requires updated clinical documentation, often including weight-loss response.
6. If denied: You can appeal in writing, and your prescriber can request a peer-to-peer review.

If your prescriber's office is unfamiliar with the MassHealth GLP-1 PA pathway, a cash-pay telehealth provider may move faster — though the medication itself will not be reimbursed.

Frequently asked questions

Does MassHealth cover Ozempic for weight loss?

No. MassHealth covers Ozempic for the FDA-approved indication of type 2 diabetes, not for weight loss in non-diabetic members. If you have type 2 diabetes, Ozempic is generally covered with prior authorization. If you want semaglutide for weight loss specifically, the on-label medication is Wegovy, which is covered under tighter PA and BMI criteria.

How do I get Wegovy covered by MassHealth?

Wegovy is covered with prior authorization. Typical criteria include a BMI of 30 or higher (or 27 with a weight-related comorbidity), documentation of a structured weight-management attempt, and ongoing-response criteria at reauthorization (commonly around 5% body-weight loss at 12 weeks). Have your prescriber submit the PA with full clinical documentation. Specific criteria vary by plan — confirm with member services.

Is Mounjaro on the MassHealth formulary?

Yes — for type 2 diabetes. Mounjaro (tirzepatide) is generally covered for members with documented type 2 diabetes, typically with prior authorization confirming the diagnosis and step-therapy history. It is not covered when prescribed off-label for weight loss in non-diabetic members.

What if MassHealth denies my GLP-1?

You have a right to appeal. Your prescriber can submit additional documentation and request a peer-to-peer review. If appeals fail, options include switching to a covered drug (if you qualify for the type 2 diabetes indication), pursuing manufacturer patient-assistance programs, or moving to a cash-pay telehealth program offering compounded GLP-1s.

Can I use MassHealth at a telehealth provider for GLP-1?

Most national cash-pay telehealth weight-loss programs (Ro Body Program, Remedy Meds, Hims) do not bill MassHealth. For MassHealth-billable telehealth, look for in-state Massachusetts providers contracted with MassHealth — your prescriber's office or a MassHealth navigator can help identify these.

Are there cheaper GLP-1 options if MassHealth won't cover it?

Yes. Cash-pay compounded semaglutide and tirzepatide programs in 2026 commonly run in the $200–$400 per month range, well below brand-name retail. These are not insurance-covered. Manufacturer patient-assistance programs may also lower out-of-pocket costs for eligible patients on brand-name Wegovy or Zepbound.

Does MassHealth Cover GLP-1 Weight Loss Drugs in 2026?